Globus Medical
$ 96.22
4.72%
25 Feb - close price
- Market Cap 12,995,208,000 USD
- Current Price $ 96.22
- High / Low $ 96.33 / 90.87
- Stock P/E 31.14
- Book Value 32.68
- EPS 3.09
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.10 %
- 52 Week High 101.40
- 52 Week Low 51.79
About
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Analyst Target Price
$109.54
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-04 | 2025-08-07 | 2025-05-08 | 2025-02-18 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.28 | 1.18 | 0.86 | 0.68 | 0.84 | 0.83 | 0.75 | 0.72 | 0.6 | 0.57 | 0.63 | 0.53 |
| Estimated EPS | 1.1536 | 0.77 | 0.75 | 0.74 | 0.7486 | 0.65 | 0.68 | 0.57 | 0.61 | 0.57 | 0.59 | 0.51 |
| Surprise | 0.1264 | 0.41 | 0.11 | -0.06 | 0.0914 | 0.18 | 0.07 | 0.15 | -0.01 | 0 | 0.04 | 0.02 |
| Surprise Percentage | 10.957% | 53.2468% | 14.6667% | -8.1081% | 12.2095% | 27.6923% | 10.2941% | 26.3158% | -1.6393% | 0% | 6.7797% | 3.9216% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMED
2026-02-14 01:48:00
This article analyzes Globus Medical Inc. Class A (NASDAQ: GMED), noting divergent sentiment across all time horizons and suggesting choppy conditions. It highlights an "exceptional 54.6:1 risk-reward short setup" targeting a 15.5% downside with minimal risk. The article provides institutional trading strategies for long, breakout, and hedging along with multi-timeframe signal analysis, and AI-generated support and resistance levels.
2026-02-13 12:27:42
This article analyzes Globus Medical's (GMED) stock valuation using two methods: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. The DCF analysis suggests GMED is undervalued by 25.8%, with an intrinsic value of $118.77 per share compared to its current price of $88.09. However, the P/E ratio of 27.82x, which is above its 'Fair Ratio' of 23.99x, indicates the stock might be overvalued based on this metric.
2026-02-12 01:58:08
Globus Medical (GMED) is currently trading around $88.72, with recent share price returns being mixed, suggesting a cooling of short-term momentum despite stronger long-term performance. Valuation models, particularly one widely followed narrative, suggest the stock is 16.6% undervalued, with a fair value of $106.40, driven by innovation in robotics and minimally invasive procedures. However, the article notes potential execution risks from prolonged sales cycles or integration issues that could impact growth and margins.
2026-02-09 01:58:08
Globus Medical (GMED) is attracting attention due to strong fundamentals, a debt-free balance sheet, and rapid expansion in musculoskeletal technologies, including its ExcelsiusGPS robotic platform. While the company's innovation in robotics and digitization presents growth opportunities, it also faces challenges like longer sales cycles and integration post-acquisitions. Investors are weighing these factors, with various fair value estimates suggesting mixed outlooks on the stock's future performance.
2026-02-05 01:58:54
This article analyzes Globus Medical's (GMED) pricing after a healthcare sector reassessment, using discounted cash flow (DCF) and price-to-earnings (P/E) ratio models. The DCF model suggests GMED is 24.3% undervalued, while the P/E ratio indicates it is overvalued compared to its proprietary "Fair Ratio." The article encourages investors to use "Narratives" on Simply Wall St to personalize their valuation based on individual assumptions.
2026-02-01 03:33:02
An investor letter from Meridian Growth Fund highlighted Globus Medical's reaccelerating spine business growth and successful integration of prior acquisitions, leading to a recent 50.16% share price increase over 90 days. Despite trading at a premium to its 1-year performance, the stock remains undervalued by 14.8% according to some narratives, with a fair value target of $106.40, driven by innovation in robotics and digital healthcare. However, challenges like slower international progress and ongoing integration work could temper this optimistic outlook.
